Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.66 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320295 | 0.84 | SCN9A (0.58) | SCN9ASCN5ASLC22A12 | |
| SCHEMBL16108028 | 0.84 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL320294 | 0.83 | SCN9A (0.62) | SCN9A | |
| SCHEMBL16530941 | 0.82 | SCN9A (1.00) | SCN9A | |
| SCHEMBL14698735 | 0.81 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL16177965 | 0.81 | SCN9A (0.60) | SCN9ASCN5A | |
| SCHEMBL327028 | 0.80 | SCN9A (0.62) | SCN9A | |
| SCHEMBL322817 | 0.80 | SCN9A (0.64) | SCN9ASCN5ASLC22A12 | |
| SCHEMBL16530805 | 0.80 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16531611 | 0.80 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-2906558-B1 | SODIUM CHANNEL BLOCKERS, PREPARATION METHOD THEREOF AND USE THEREOF | DAE WOONG PHARMA (KR) | 2020-09-02 | — | — | EP | disclosed |
| WO-2020119616-A1 | BENZENE SULFONAMIDE SUBSTITUTED DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2020-06-18 | — | — | WO | disclosed |
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3148992-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9376429-B2 | Sodium channel blockers, preparation method thereof and use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-28 | — | — | US | disclosed |
| WO-2015181797-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150336944-A1 | Sodium Channel Blockers, Preparation Method Thereof and Use Thereof | IN THERAPEUTICS (KR) | 2015-11-26 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN5A 19/4885SLC22A12 999/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | SCN9A 32/4885SCN5A 30/4885SLC22A12 706/4885 |
| US-20150336944-A1 | Sodium Channel Blockers, Preparation Method Thereof and Use Thereof | SCN7A, SCN1A, SCN5A | SCN9A 8/4885SCN5A 3/4885SLC22A12 1041/4885 |
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN2B | SCN9A 13/4885SCN5A 11/4885SLC22A12 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.